Analysts are on the Bearish side about Verastem Inc (NASDAQ:VSTM) this week.

October 13, 2017 - By Linda Rogers

 Analysts are on the Bearish side about Verastem Inc (NASDAQ:VSTM) this week.
Investors sentiment increased to 1.17 in 2017 Q2. Its up 0.07, from 1.1 in 2017Q1. It increased, as 5 investors sold Verastem Inc shares while 18 reduced holdings. 13 funds opened positions while 14 raised stakes. 8.68 million shares or 12.61% more from 7.71 million shares in 2017Q1 were reported.
Tfs Cap Ltd invested in 0.03% or 29,495 shares. Awm Inv Inc reported 50,000 shares or 0.02% of all its holdings. Grt Capital Prtnrs Lc stated it has 0.03% of its portfolio in Verastem Inc (NASDAQ:VSTM). Beaumont Partners Limited Company has 10,000 shares for 0% of their portfolio. Connor Clark & Lunn Mngmt Limited holds 299,125 shares. Jpmorgan Chase And accumulated 251 shares. Savings Bank Of Ny Mellon reported 31,022 shares or 0% of all its holdings. California Employees Retirement System holds 0% of its portfolio in Verastem Inc (NASDAQ:VSTM) for 91,300 shares. Goldman Sachs Group accumulated 18,192 shares or 0% of the stock. Nationwide Fund Advsr, Pennsylvania-based fund reported 13,468 shares. Deer Vii And holds 84.34% of its portfolio in Verastem Inc (NASDAQ:VSTM) for 1.19M shares. Lpl Finance stated it has 19,494 shares or 0% of all its holdings. Federated Pa holds 0% of its portfolio in Verastem Inc (NASDAQ:VSTM) for 1,293 shares. Fmr Ltd Liability Com owns 250,000 shares or 0% of their US portfolio. Moreover, Alpine Woods Cap Limited Com has 0.01% invested in Verastem Inc (NASDAQ:VSTM) for 50,040 shares.

Since May 15, 2017, it had 1 insider buy, and 0 sales for $73,500 activity.

Verastem Inc (NASDAQ:VSTM) Ratings Coverage

Among 10 analysts covering Verastem (NASDAQ:VSTM), 4 have Buy rating, 0 Sell and 6 Hold. Therefore 40% are positive. Verastem had 26 analyst reports since September 9, 2015 according to SRatingsIntel. Oppenheimer maintained the shares of VSTM in report on Tuesday, August 8 with “Buy” rating. The rating was downgraded by Roth Capital on Monday, September 28 to “Neutral”. Oppenheimer maintained the stock with “Buy” rating in Monday, June 26 report. The rating was downgraded by JMP Securities to “Mkt Perform” on Tuesday, September 29. Oppenheimer maintained the shares of VSTM in report on Sunday, June 4 with “Buy” rating. The firm earned “Buy” rating on Friday, March 24 by H.C. Wainwright. The stock of Verastem Inc (NASDAQ:VSTM) has “Hold” rating given on Thursday, June 8 by Cantor Fitzgerald. UBS downgraded Verastem Inc (NASDAQ:VSTM) on Tuesday, September 29 to “Neutral” rating. The stock has “Neutral” rating by TH Capital on Monday, September 28. The firm has “Buy” rating given on Wednesday, August 16 by Oppenheimer. Below is a list of Verastem Inc (NASDAQ:VSTM) latest ratings and price target changes.

25/09/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $17.0 Maintain
06/09/2017 Broker: Cantor Fitzgerald Old Rating: Neutral New Rating: Overweight Upgrade
16/08/2017 Broker: Oppenheimer Rating: Buy Maintain
10/08/2017 Broker: H.C. Wainwright Rating: Buy New Target: $6.5000
08/08/2017 Broker: Oppenheimer Rating: Buy New Target: $6.0000 Maintain
25/07/2017 Broker: Oppenheimer Rating: Buy New Target: $6.0000 Maintain
12/07/2017 Broker: Oppenheimer Rating: Buy New Target: $6.0000 Maintain
26/06/2017 Broker: Jefferies Rating: Hold New Target: $1.5000 Maintain
26/06/2017 Broker: Oppenheimer Rating: Buy New Target: $6.0000 Maintain
16/06/2017 Broker: Oppenheimer Rating: Buy New Target: $6.0000 Maintain

The stock decreased 3.97% or $0.18 on October 13, reaching $4.35. About 717,648 shares traded. Verastem Inc (NASDAQ:VSTM) has risen 71.53% since October 13, 2016 and is uptrending. It has outperformed by 54.83% the S&P500.

Verastem, Inc. is a biopharmaceutical company. The company has market cap of $160.92 million. The Firm is focused on discovering and developing drugs to improve outcomes for patients with cancer. It currently has negative earnings. The Firm operates in the segment of developing drugs for the treatment of cancer.

Another recent and important Verastem Inc (NASDAQ:VSTM) news was published by Businesswire.com which published an article titled: “Verastem Appoints NgocDiep Le, MD, PhD as Chief Medical Officer” on October 11, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.